CoChat

CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity

Open access
Yang, Chenyi, Boyson, Cynthia A., Di Liberto, Maurizio, Huang, Xiangao, Hannah, Jeffrey, Dorn, David C., Moore, Malcolm A.S., Chen-Kiang, Selina, Zhou, Pengbo · 2015 · Cancer Research

Published version of a preprint

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Cyclin-dependent kinase (CDK)4 and CDK6 are frequently overexpressed or hyperactivated in human cancers. Targeting CDK4/CDK6 in combination with cytotoxic killing therefore represents a rational approach to cancer therapy. By selective inhibition of CDK4/CDK6 with PD 0332991, which leads to early G1 arrest and synchronous S-phase entry upon release of the G1 block, we have developed a novel strategy to prime acute myeloid leukemia (AML) cells for cytotoxic killing by cytarabine (Ara-C). This sensitization is achieved in part through enrichment of S-phase cells, which maximizes the AML populations for Ara-C incorporation into replicating DNA to elicit DNA damage. Moreover, PD 0332991 triggered apoptosis of AML cells through inhibition of the homeobox (HOX)A9 oncogene expression, reducing the transcription of its target PIM1. Reduced PIM1 synthesis attenuates PIM1-mediated phosphorylation of the proapoptotic BAD and activates BAD-dependent apoptosis. In vivo, timely inhibition of CDK4/CDK6 by PD 0332991 and release profoundly suppresses tumor growth in response to reduced doses of Ara-C in a xenograft AML model. Collectively, these data suggest selective and reversible inhibition of CDK4/CDK6 as an effective means to enhance Ara-C killing of AML cells at reduced doses, which has implications for the treatment of elderly AML patients who are unable to tolerate high-dose Ara-C therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-14-2486

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 1

  1. Ries, SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD. Ref Type: Electronic Citation.

Cited by

See all 74

Metadata

Authors
Yang, C., Boyson, C. A., Di Liberto, M., Huang, X., Hannah, J., Dorn, D. C., Moore, M. A. S., Chen-Kiang, S., & Zhou, P.
Affiliations
  • Weill Cornell Medicine (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • 1Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York.
Corresponding author
Zhou, Pengbo
Venue
Cancer Research
Published
2015-04-30
Volume
75
Issue
9
Pages
1838-1845
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W1994922459
Cited by
62
References
27
Citations by year
2026: 3 · 2025: 8 · 2024: 4 · 2023: 5 · 2022: 6 · 2021: 8 · 2020: 8 · 2019: 7 · 2018: 2 · 2017: 3 · 2016: 5 · 2015: 3
FWCI
3.40
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Cancer Research Institute
  • Pfizer
  • National Institutes of Health
  • National Cancer Institute (R01CA098210, R01CA120531, R01CA159925)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
CDK4/6 inhibition, palbociclib, acute myeloid leukemia, cytarabine, combination therapy, G1/S cell cycle arrest, DNA damage, apoptosis, HOXA9, PIM-1, Bad phosphorylation, xenograft tumor growth, elderly patients
MeSH terms
Animals, Antineoplastic Agents, Cell Line, Cytarabine, DNA Damage, DNA Replication, Humans, Phosphorylation, Piperazines, Pyridines, Transcription, Genetic, Tumor Cells, Cultured, Leukemia, Myeloid, Acute, S Phase, Mice, SCID, Mice, Inbred NOD, Apoptosis, HL-60 Cells, Xenograft Model Antitumor Assays, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Proto-Oncogene Proteins c-pim-1, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-2486
The paper
Yang, C., Boyson, C. A., Di Liberto, M., Huang, X., Hannah, J., Dorn, D. C., Moore, M. A. S., Chen-Kiang, S., & Zhou, P. (2015). CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-2486

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.